Rotigotine Transdermal Patch in Chinese Patients with Early Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Pivotal Study
Zhen-Xin Zhang,Hui-Fang Shang,Xingyue Hu,Shengdi Chen,Zhongxin Zhao,Xinlu Du,Erwin Surmann,Lars Bauer,Mahnaz Asgharnejad
DOI: https://doi.org/10.1016/j.parkreldis.2016.04.022
2017-01-01
Abstract:Introduction: Two phase3 studies (SP512; SP513) involving mostly Caucasian patients showed that rotigotine (<= 8 mg/24 h) was efficacious and welltolerated in early-stage Parkinson's disease (PD). We report results from a phase 3 study (SP0914/NCT01646268) investigating rotigotine in Chinese patients with early-stage PD.Methods: Patients were randomized 1:1 to rotigotine or placebo, titrated over 1-4 weeks, maintained at optimal/maximum dose (<= 8 mg/24 h) for 24 weeks. Primary efficacy variable: change in Unified Parkinson's Disease Rating Scale (UPDRS) II + III total score from Baseline to End-of-Maintenance. Secondary variables: UPDRS II + III responders (>= 20% decrease in UPDRS II + III) and changes in UPDRS II (activities of daily living [ADL]) and III (motor examination) subscores.Results: Of 247 patients randomized, 113/124 (91.1%) rotigotine- and 107/123 (87.0%) placebo-treated patients completed the study. Patients: mean (SD) age: 59.4 (10.2) years; time since PD diagnosis: 1.01 (1.22) years, 60.7% male. Rotigotine significantly improved UPDRS II + Ill total score (change from Baseline LSmean [95%CI] treatment difference, -4.82 [-7.18 to -2.45]; P < 0.0001). UPDRS II + III responder rates were higher with rotigotine (42.3% vs 22.3%; P = 0.0006). UPDRS II and III subscores improved with rotigotine (both subscores: P < 0.0005 vs. placebo). Most frequent adverse events (AEs): nausea (8.9% rotigotine, 3.3% placebo), dizziness (8.1%, 5.7%), pruritus (8.1%, 4.1%), somnolence (8.1%, 3.3%), erythema (6.5%, 1.6%), and vomiting (5.6%, 1.6%). Thirteen (53%) patients discontinued due to AEs (6 rotigotine, 7 placebo).Conclusions: Rotigotine was efficacious in Chinese patients with early-stage PD, providing benefits to control of ADL and motor function. Rotigotine was generally welltolerated, with similar AEs to those observed in Caucasian patients. (C) 2016 Elsevier Ltd. All rights reserved.